They had four irons in the fire in 2020/21, I figured they'd get at least 1 or 2. I was wrong. I don't want to get into a MSB vs CYP scale/consistency fight. If MSB get approved by the FDA then the regulatory path undeniably easier for CYP - as it clearly is for all stem cell treatments in 2023, than 2021/21.
MSB has far more breadth and depth of evidence now and has consulted the FDA to the nth degree. They should get over the line, but if you feel they won't, then the regulatory path probably a little longer and harder for CYP and you apply a lower execution probability. Either way, CYP is absurdly valued at $24 million, by even the most pessimistic of forecasts.
They had four irons in the fire in 2020/21, I figured they'd get...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.010(4.00%) |
Mkt cap ! $43.36M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.0¢ | $23.56K | 97.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18606 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |